Distribution of cell cycle times amongst the leukemia cells within individual patients with acute myelogenous leukemia

Seventeen patients with AML received infusions of BrdUrd to permit measurement of the cell parameters of leukemia cells in vivo. The range of S-phase times was measured by using a two color BrdUrd/Pl analysis to determine the range of BrdUrd incorporation into cells which had been in S-phase throughout the entire duration of BrdUrd administration. These data were, in turn, used to calculate the range of cell cycle times amongst the leukemia cells present within individual patients. The range of cell cycle times amongst the leukemia cells present within individual patients differs between patients, with some leukemia cell populations characterized by narrow and others by broad ranges. In general, the longer the mean cell cycle time (between 27 and 112 h) the broader the range of cell cycle times. These differences may help to explain, in part, the differences in response to therapy among patients whose mean leukemia cell kinetic parameters are similar.

The study of acute leukemia cells by means of acridine orange staining and flow cytometry

The studies described here explored the staining of acute leukemia cells with acridine orange (AO). The red fluorescence curve of AML specimens was usually bimodal, suggesting the presence of subpopulations of cells which have different RNA contents. In almost every AML specimen, small leukemic blast cells comprised at least part of the "low RNA content" subpopulation. Residual granulocytes and lymphocytes also contributed to this population. Frequently, the green fluorescence, indicative of the binding of AO to DNA, was slightly less in these cells than in the majority of cells present. There was no evidence however, that the leukemia cells with these characteristics represented a G0 or kinetically quiescent population of cells. In ALL specimens, the presence of multiple cytogenetically distinct clones was easily detectable in AO stained specimens. The red fluorescence curve of G0/G1 ALL cells was unimodal.

Cell cycle parameters and DNA ploidy in colorectal carcinomas

Seven patients with colorectal adenocarcinoma and one with squamous cell carcinoma of anorectal region were infused preoperatively with iododeoxyuridine (IUdR) and bromodeoxyuridine (BrdU) in sequence (100 mg/m2 x 1 hr each with 1-hr interval in between) to label S-phase cells. The tumor biopsy specimens were embedded in glycol-methacrylate and 2-microns thick sections were treated with two monoclonal antibodies which permitted the identification of cells which incorporated IUdR only, BrdU only, both IUdR and BrdU, or neither IUdR or BrdU. The labeling index of tumors varied from 17.3 to 35.6% (mean = 25.78 +/- 6.162), duration of S-phase ranged from 14.0 to 23.9 hr (mean = 18.73 +/- 3.712), and total cell cycle time ranged from 39.4 to 123.4 hr (mean = 76.78 +/- 24.165). The architecture of the tumor was well preserved and a variable number of DNA synthesizing mononuclear cells were identified within and around the tumor. Image analysis of Feulgen-stained smears of the tumors was done to measure the DNA content of seven tumor samples. Each tumor was found to be hyperdiploid with multiple modal values. The studies described here demonstrate the feasibility of performing cell cycle kinetic measurements on gastrointestinal tumors which have been labeled in vivo. The ability to perform these measurements on tumor biopsies allows the avoidance of artifacts introduced when solid tumors are disaggregated in vitro for study.

Cell cycle kinetic studies in human cancers. Development of three DNA-specific labels in three decades

Controversy has epitomized the prognostic and clinical significance accorded to cell cycle kinetic studies in neoplastic diseases. Recent introduction of monoclonal antibodies to thymidine analogues such as iododeoxyuridine and bromodeoxyuridine has unveiled a spectacular new area of research. Large numbers of patients with liquid and solid tumors have been interrogated by introducing iododeoxyuridine and bromodeoxyuridine as DNA-specific probes in vivo. Further in vitro incubation of S-phase cells already double-labeled in vivo with tritiated thymidine has added a whole new dimension to the kinds of questions that can now be addressed with alacrity. Time is rapidly approaching when this information will be available in a prompt enough fashion to be useful for planning therapeutic strategies. Reviewed are the salient features of the rapid progress achieved in the last decade in this exciting discipline.